• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Enovis Corporation

    5/19/26 4:57:30 PM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on May 19, 2026

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Enovis Corporation

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   54-1887631
    (State or Other Jurisdiction of   (I.R.S. Employer
    Incorporation or Organization)   Identification No.)
       
    2711 Centerville Road, Suite 400    
    Wilmington, DE   19808
    (Address of Principal Executive Offices)   (Zip Code)

     

    Enovis Corporation 2020 Omnibus Incentive Plan

    (Full Title of the Plan)

     

    Damien McDonald

    Chief Executive Officer

    Enovis Corporation

    2711 Centerville Road, Suite 400

    Wilmington, DE 19808

    (302) 252-9160

    (Name, Address and Telephone of Agent for Service)

     

    Copies to:

     

    Michele L. Connell, Esq.

    Squire Patton Boggs (US) LLP

    1000 Key Tower

    127 Public Square

    Cleveland, OH 44114

    (216) 479-8500

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

           
    Large accelerated filer ☒ Accelerated filer ☐
           
    Non-accelerated filer ☐ Smaller reporting company ☐
           
    Emerging Growth Company ☐    

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is filed by Enovis Corporation (the “Company”) and relates to 3,650,000 shares of common stock, par value $0.001 per share (“Common Stock”), issuable under the Enovis Corporation 2020 Omnibus Incentive Plan, as amended (the “Plan”), which shares of Common Stock are in addition to (i) the 1,476,666 shares of Common Stock (as adjusted for the one-for-three reverse stock split effected by the Company on April 4, 2022) registered on the Company’s Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on May 21, 2020 (File No. 333-238564), (ii) the 745,000 shares of Common Stock registered on the Company’s Form S-8 filed with the Commission on August 4, 2022 (File No. 333-266526) and (iii) the 2,100,000 shares of Common Stock registered on the Company’s Form S-8 filed with the Commission on June 26, 2024 (File No. 333-280490) (together, the “Prior Registration Statements”). An amendment of the Plan, including an increase of 3,650,000 shares of Common Stock available for issuance thereunder, was approved at the Company’s 2026 Annual Meeting of Stockholders held on May 19, 2026 as previously reported on the Company’s Current Report on Form 8-K filed with the Commission on May 19, 2026.

     

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits

     

    Exhibit No.   Description
         
    4.1   Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.01 to the Company’s Current Report on Form 8-K, as filed with the Commission on January 30, 2012)
         
    4.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation, dated April 4, 2022 (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the Commission on April 8, 2022)
         
    4.3   Certificate of Amendment to the Amended and Restated Certificate of Incorporation, dated May 22, 2024 (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the Commission on May 22, 2024)
         
    4.4   Enovis Corporation Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, as filed with the Commission on April 8, 2022)
         
    5.1*   Opinion of Squire Patton Boggs (US) LLP
         
    23.1*   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
         
    23.2*   Consent of Squire Patton Boggs (US) LLP (included in Exhibit 5.1)
         
    24.1*   Power of Attorney of Enovis Corporation (included on signature page hereto)
         
    99.1   Enovis Corporation 2020 Omnibus Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the Commission on May 27, 2020)
         
    99.2   First Amendment to the Enovis Corporation 2020 Omnibus Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the Commission on June 13, 2022)
         
    99.3   Second Amendment to Enovis Corporation 2020 Omnibus Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the Commission on May 22, 2024)
         
    99.4   Third Amendment to Enovis Corporation 2020 Omnibus Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the Commission on May 19, 2026)
         
    107*   Filing Fee Table

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wilmington, State of Delaware, on this 19th day of May, 2026.

     

      ENOVIS CORPORATION
         
      By:

    /s/ Damien McDonald

        Damien McDonald
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Damien McDonald and Bradley J. Tandy, and each of them severally, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated below.

     

    Signature   Title   Date
         

    /s/ Damien McDonald

    Damien McDonald

      Chief Executive Officer and Director (Principal Executive Officer)   May 19, 2026
         

    /s/ Phillip B. Berry

    Phillip B. Berry

      Senior Vice President and Chief Financial Officer (Principal Financial Officer)   May 19, 2026
         

    /s/ John Kleckner

    John Kleckner

      Vice President, Controller and Chief Accounting Officer (Principal Accounting Officer)   May 19, 2026
         

    /s/ Barbara W. Bodem

    Barbara W. Bodem

      Director   May 19, 2026
         

    /s/ Liam J. Kelly

    Liam J. Kelly

      Director   May 19, 2026
         

    /s/ Angela S. Lalor

    Angela S. Lalor

      Director   May 19, 2026
             

    /s/ Philip A. Okala

    Philip A. Okala

      Director   May 19, 2026
         

    /s/ Dr. Christine Ortiz

    Dr. Christine Ortiz

      Director   May 19, 2026
         

    /s/ A. Clayton Perfall

    A. Clayton Perfall

      Director   May 19, 2026
         

    /s/ Brady R. Shirley

    Brady R. Shirley

      Director   May 19, 2026
         

    /s/ Rajiv Vinnakota

    Rajiv Vinnakota

      Director   May 19, 2026
         

    /s/ Sharon L. Wienbar

    Sharon L. Wienbar

      Director   May 19, 2026

     

     

     

    Get the next $ENOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    4/17/2026Outperform
    William Blair
    1/6/2026$41.00Buy
    BTIG Research
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    More analyst ratings

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enovis Announces First Quarter 2026 Results

    First-quarter sales growth of 5% on a reported basisFirst-quarter Reconstructive sales grew 11% on a reported basisReiterating full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion guidance Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2026 Financial Results Enovis' first-quarter net sales of $589 million grew 5% on a reported basis and 3

    5/7/26 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Host First Quarter 2026 Results Conference Call on May 7th

    Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results on Thursday, May 7th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-987

    4/10/26 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

    Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter 2025 Financial Results Enovis' fo

    2/26/26 6:33:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    SEC Filings

    View All

    SEC Form SD filed by Enovis Corporation

    SD - Enovis CORP (0001420800) (Filer)

    5/28/26 5:21:46 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form S-8 filed by Enovis Corporation

    S-8 - Enovis CORP (0001420800) (Filer)

    5/19/26 4:57:30 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Enovis CORP (0001420800) (Filer)

    5/19/26 4:54:13 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Administrative Officer Engert Oliver bought $22,220 worth of shares (1,000 units at $22.22), increasing direct ownership by 2% to 49,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    6/3/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $23,740 worth of shares (1,000 units at $23.74), increasing direct ownership by 2% to 48,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    3/16/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $23,930 worth of shares (1,000 units at $23.93), increasing direct ownership by 2% to 47,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    3/12/26 7:35:49 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Administrative Officer Engert Oliver bought $22,220 worth of shares (1,000 units at $22.22), increasing direct ownership by 2% to 49,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    6/3/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Director Shirley Brady was granted 9,346 shares, increasing direct ownership by 9% to 110,589 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    5/21/26 8:30:14 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Director Lalor Angela S was granted 9,346 shares, increasing direct ownership by 42% to 31,486 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    5/21/26 8:30:08 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair resumed coverage on Enovis Corporation

    William Blair resumed coverage of Enovis Corporation with a rating of Outperform

    4/17/26 8:10:50 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    BTIG Research initiated coverage on Enovis Corporation with a new price target

    BTIG Research initiated coverage of Enovis Corporation with a rating of Buy and set a new price target of $41.00

    1/6/26 8:55:57 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    JMP Securities initiated coverage on Enovis Corporation with a new price target

    JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

    10/3/24 7:29:21 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    View All

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $ENOV
    Financials

    Live finance-specific insights

    View All

    Enovis Appoints Oliver Engert as Chief Administrative Officer

    Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis' strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its next phase of profitable, capital-efficient growth. Damien McDonald, CEO of Enovis said, "Oliver's appointment comes at a very exciting time for Enovis. As we take steps to build on our strong foundation and unlock our future potential, his extensive knowledge, skills a

    1/5/26 4:15:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

    Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

    4/2/25 6:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

    NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

    1/7/25 6:19:00 PM ET
    $ARCH
    $CART
    $CEIX
    Coal Mining
    Energy
    Real Estate
    Industrial Specialties

    Amendment: SEC Form SC 13G/A filed by Enovis Corporation

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    11/14/24 1:28:31 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    4/5/24 12:21:51 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    2/14/24 10:04:36 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces First Quarter 2026 Results

    First-quarter sales growth of 5% on a reported basisFirst-quarter Reconstructive sales grew 11% on a reported basisReiterating full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion guidance Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2026 Financial Results Enovis' first-quarter net sales of $589 million grew 5% on a reported basis and 3

    5/7/26 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Host First Quarter 2026 Results Conference Call on May 7th

    Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results on Thursday, May 7th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-987

    4/10/26 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

    Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter 2025 Financial Results Enovis' fo

    2/26/26 6:33:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care